AstraZeneca shared positive results from the company’s TOPAZ-1 Phase III trial on Imfinzi (durvalumab) in increasing the chances for survival in advanced biliary tract cancer patients when combined with standard-of-care chemotherapy regimens.
Durect Corporation inked a development and commercialization deal with Sandoz AG, a division of Novartis AG, totaling around $293 million.
